KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $60.5 million.

  • Jazz Pharmaceuticals' Shares Outstanding (Weighted Average) fell 1.77% to $60.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.7 million, marking a year-over-year decrease of 1.77%. This contributed to the annual value of $60.5 million for FY2024, which is 3.97% down from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Shares Outstanding (Weighted Average) of $60.5 million as of FY2024, which was down 3.97% from $63.0 million recorded in FY2023.
  • In the past 5 years, Jazz Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $63.0 million during FY2022, and its lowest value of $55.7 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $62.1 million, with a median of $63.0 million in 2023.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first climbed by 10.33% in 2021, then dropped by 3.97% in 2024.
  • Over the past 5 years, Jazz Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $55.7 million in 2020, then increased by 10.33% to $61.5 million in 2021, then climbed by 2.43% to $63.0 million in 2022, then dropped by 0.01% to $63.0 million in 2023, then dropped by 3.97% to $60.5 million in 2024.